Sheldon Koenig, MBA

Sheldon Koenig, MBA has extensive work experience in the pharmaceutical and biotech industries. Sheldon is currently a Board Member & Co-Founder of Nuvig Therapeutics Inc. Prior to this, they served as the President and CEO of Esperion Therapeutics and the Chief Operating Officer of Esperion. Before joining Esperion, Sheldon was the Executive Vice President and Chief Commercial Officer at Portola Pharmaceuticals.

In 2018, Sheldon established their own advisory firm called SL Koenig & Associates, LLC, where they provided commercialization strategies for venture capital firms, startups, and pharmaceutical companies. Prior to this, they held a senior leadership position at Sanofi, where they led the global CV franchise and U.S. business operations for Praluent.

Sheldon's career at Merck spanned over two decades, during which they held various leadership roles within the Global Cardiovascular and Thrombosis franchises. Sheldon served as the Vice President and Global Brand Leader for Thrombosis & CV New Products, as well as the Executive Director of Global Brand Marketing-Cardiovascular. At Merck, they led successful marketing and commercialization processes for several medications and played a key role in global go-to-market strategies.

Overall, Sheldon Koenig has demonstrated expertise in commercialization, branding, marketing, and team leadership within the pharmaceutical and biotech industries.

Sheldon Koenig, MBA, earned their Bachelor of Applied Science degree in Accounting from Drexel University. Sheldon later pursued their MBA in Marketing from Monmouth University. Additionally, they completed the Leadership Program at The Wharton School.